Meeting
2022 ASCO Annual Meeting
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
Authors
Dirk Schadendorf
Department of Dermatology, University Hospital Essen, Essen, Germany
Dirk Schadendorf , Helen Gogas , Lidija Kandolf Sekulovic , Friedegund Elke Meier , Thomas Eigentler , Jan-Christoph Simon , Patrick Andres Maximilian Terheyden , Anja Heike Gesierich , Rudolf Alexander Herbst , Katharina C. Kähler , Dimitrios C. Ziogas , Zeljko Mijuskovic , Marlene Garzarolli , Claus Garbe , Alexander Roesch , Selma Ugurel , Ralf Gutzmer , Jean-Jacques Grob , Lisa Zimmer , Elisabeth Livingstone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02902029
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9548)
DOI
10.1200/JCO.2022.40.16_suppl.9548
Abstract #
9548
Poster Bd #
141
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2022 ASCO Annual Meeting
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
First Author: Debbie Robbrecht
Poster
2021 ASCO Annual Meeting
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
First Author: Caroline Robert